bone marrow and peripheral blood aml cells are highly sensitive to cndac, the active form of sapacitabine骨髓和外周血aml细胞cndac高度敏感,sapacitabine的活性形式.pdfVIP

Hindawi Publishing Corporation Advances in Hematology Volume 2012, Article ID 727683, 12 pages doi:10.1155/2012/727683 Research Article Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine Sucheta Jagan,1, 2, 3 Laura A. Paganessi,1, 2, 3 Robin R. Frank,1, 2, 3 Parameswaran Venugopal,2, 3 Melissa Larson,2, 3 and Kent W. Christopherson II1, 2, 3, 4 1 Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA 2 Rush University Cancer Center, 1725 West Harrison Street, Chicago, IL 60612, USA 3 Section of Hematology, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA 4 Department of Anatomy and Cell Biology, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA Correspondence should be addressed to Kent W. Christopherson II, kent christopherson@ Received 18 June 2012; Accepted 4 August 2012 Academic Editor: Seiji Fukuda Copyright © 2012 Sucheta Jagan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Achieving improvements in survival and reducing relapse remains a challenge in acute myelogenous leukemia (AML) patients. This study evaluated the in vitro efficacy of the active form of novel agent sapacitabine, CNDAC, compared to current chemotherapeutic drugs Ara-C and mitoxantrone using two AML cell lines, HL-60 (promyelocytic) and THP-1 (monocytic), as well as bone marrow (BM) and peripheral blood (PB) cells collected from AML patients. Cell lines were exposed to compound for 3–6 days and primary cells for 4 da